HIV patients fare well with mpox treatment

Patients with HIV had similar treatment outcomes to patients without HIV when treated for mpox with an antiviral drug called tecovirimat, according to a new study.

Epigenetic drug aids chemotherapy in lymphoma study

Nearly 90% of patients with an aggressive subtype of non-Hodgkin lymphoma had their cancer go into remission in a small phase 2 clinical trial testing a treatment aimed at making chemotherapy more effective, according to Weill Cornell Medicine and NewYork-Presbyterian investigators.

Alum’s software helps teachers know what’s working in the classroom

The next episode of Startup Cornell features Nona Ullman ‘88, an entrepreneur creating software to help teachers.

Around Cornell

Big Red Ventures showcases portfolio at Annual Meeting

Big Red Ventures (BRV), Cornell’s early-stage venture capital fund, showcased the student-run portfolio and highlighted 2022-23 investments during the Annual Meeting on April 20 at Cornell Tech.

Around Cornell

Weill Cornell Medicine celebrates two landmark anniversaries

Weill Cornell Medicine commemorates 125 years since its founding, and 25 years since its renaming.

Milstein first-years take advantage of community, opportunity

The first-year class of students in the Milstein Program in Technology and Humanity are finishing up their community projects and looking forward to their summer in New York City.

Around Cornell

Incubator to support projects for work and social change

The Yang-Tan WorkABILITY Incubator, recently launched through the ILR School’s Center for Applied Research on Work, will support innovative applied research projects and collaborations.

Interfering with antiviral pathway may deter Alzheimer’s

Targeting part of a key antiviral pathway may one day offer a new therapeutic approach to deterring or delaying cognitive decline, according to preclinical research led by Weill Cornell Medicine scientists.

Trial shows strong COVID protection in antibody combination

A treatment combining two antibodies against the coronavirus SARS-CoV-2 strongly protected high-risk people with early COVID-19 symptoms from hospitalization and death in an international Phase 2/3 clinical trial.